Breyer Didier, Herman Philippe, Brandenburger Annick, Gheysen Godelieve, Remaut Erik, Soumillion Patrice, Van Doorsselaere Jan, Custers René, Pauwels Katia, Sneyers Myriam, Reheul Dirk
Scientific Institute of Public Health, Division of Biosafety and Biotechnology, Brussels, Belgium.
Environ Biosafety Res. 2009 Apr-Jun;8(2):57-64. doi: 10.1051/ebr/2009007. Epub 2009 Oct 16.
In the European Union, the definition of a GMO is technology-based. This means that a novel organism will be regulated under the GMO regulatory framework only if it has been developed with the use of defined techniques. This approach is now challenged with the emergence of new techniques. In this paper, we describe regulatory and safety issues associated with the use of oligonucleotide-mediated mutagenesis to develop novel organisms. We present scientific arguments for not having organisms developed through this technique fall within the scope of the EU regulation on GMOs. We conclude that any political decision on this issue should be taken on the basis of a broad reflection at EU level, while avoiding discrepancies at international level.
在欧盟,转基因生物的定义是基于技术的。这意味着,一种新型生物只有在使用特定技术开发的情况下,才会受到转基因生物监管框架的监管。随着新技术的出现,这种方法现在受到了挑战。在本文中,我们描述了与使用寡核苷酸介导的诱变技术开发新型生物相关的监管和安全问题。我们提出了科学论据,以说明通过这种技术开发的生物不应属于欧盟转基因生物法规的范围。我们得出结论,关于这个问题的任何政治决定都应该在欧盟层面进行广泛思考的基础上做出,同时避免国际层面出现差异。